...
首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Metallic stents for treatment of benign biliary obstruction: a long-term study comparing different stents.
【24h】

Metallic stents for treatment of benign biliary obstruction: a long-term study comparing different stents.

机译:用于治疗良性胆道梗阻的金属支架:比较不同支架的长期研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: To investigate the role of metallic stents in the treatment of benign biliary strictures and analyze the differences in primary patency associated with the various types of stents deployed. MATERIALS AND METHODS: Between 1990 and 1997, 21 patients with benign obstructive jaundice were treated with transhepatic placement of metallic stents (11 Wallstents in 10 patients, nine Palmaz stents in seven patients, and four tantalum Strecker stents in four patients). Nineteen patients presented with strictures not responding to balloon angioplasty (postsurgical, n = 13; cholangitis, n = 5; unknown, n = 1). Estimates for cumulative patency, patency rate in the different stent groups, and survival were calculated with use of life-table analysis; the log-rank test was used to compare the different stent groups. The prognostic relevance of the selected variables-stent type, stent length, etiology, and location-were modeled with respect to patency according to Weibull distribution. RESULTS: The median follow-up time was 80.5 months (range, 2-116 months). The median survival time was 91 months. One patient was lost to follow-up after 3 months. Repeat intervention for recurrent obstructive jaundice was necessary in 11 patients (55%), and the median patency rate was 26 months (range, 2-96 months). The Palmaz stent was the most effective in achieving long-term patency, with a median patency duration of 36 months (range, 22-96 months), versus 9 months (range, 3-67 months) for the Wallstent and 6 months (range, 2-15 months) for the tantalum Strecker stent. The cumulative patency rate with the Palmaz stent was significantly higher than for the tantalum Strecker stent (log-rank test, P = .017) and nonsignificantly higher compared with the Wallstent (log-rank test, P = .07). Multivariate analysis showed that the type of stent (Wald test, P = .003) and stent length (Wald test, P < .0001) influenced the patency rate. CONCLUSIONS: These results suggest that the type of stent and the stent length have a significant influence on the patency rate. In this series, the Palmaz stent was most effective in achieving long-term patency in benign biliary strictures.
机译:目的:探讨金属支架在良性胆道狭窄治疗中的作用,并分析与各种类型支架相关的主要通畅性的差异。材料与方法:在1990年至1997年之间,对21例良性梗阻性黄疸患者进行了金属支架置入肝内治疗(11例Wallstents患者,9例Palmaz支架患者7例和4例钽Strecker支架患者)。 19名患者表现出对球囊血管成形术无反应的狭窄(术后,n = 13;胆管炎,n = 5;未知,n = 1)。使用寿命表分析计算累积通畅性,不同支架组中通畅率和存活率的估计值;对数秩检验用于比较不同的支架组。根据Weibull分布,针对通畅性对所选变量(支架类型,支架长度,病因和位置)的预后相关性进行建模。结果:中位随访时间为80.5个月(范围2-116个月)。中位生存时间为91个月。 3个月后失去一名患者进行随访。 11例患者(55%)需要反复干预以治疗复发性阻塞性黄疸,中位通畅率为26个月(2-96个月)。 Palmaz支架在实现长期通畅方面最有效,中位通畅时间为36个月(范围22-96个月),而Wallstent和9个月(范围3-67个月)和6个月(范围) (适用于2-15个月)用于钽Strecker支架。 Palmaz支架的累积通畅率显着高于钽Strecker支架(对数秩检验,P = .017),与Wallstent(对数秩检验,P = .07)相比无明显提高。多因素分析表明,支架的类型(Wald试验,P = .003)和支架的长度(Wald试验,P <.0001)影响通畅率。结论:这些结果表明支架的类型和支架的长度对通畅率有显着影响。在该系列中,Palmaz支架在实现良性胆道狭窄的长期通畅方面最有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号